Your browser is no longer supported. Please, upgrade your browser.
Settings
XON Intrexon Corporation daily Stock Chart
XON [NASD]
Intrexon Corporation
Index- P/E- EPS (ttm)-0.70 Insider Own0.10% Shs Outstand168.15M Perf Week-5.76%
Market Cap1.71B Forward P/E- EPS next Y-1.27 Insider Trans- Shs Float136.29M Perf Month-29.85%
Income-91.10M PEG- EPS next Q-0.43 Inst Own87.20% Short Float23.14% Perf Quarter-30.00%
Sales208.00M P/S8.21 EPS this Y84.40% Inst Trans5.59% Short Ratio20.18 Perf Half Y-34.43%
Book/sh4.16 P/B2.44 EPS next Y28.60% ROA-22.10% Target Price22.75 Perf Year-25.48%
Cash/sh1.47 P/C6.90 EPS next 5Y25.80% ROE-35.00% 52W Range9.52 - 20.16 Perf YTD-11.89%
Dividend- P/FCF- EPS past 5Y58.00% ROI-8.80% 52W High-49.65% Beta1.59
Dividend %- Quick Ratio3.20 Sales past 5Y75.80% Gross Margin69.10% 52W Low6.62% ATR0.95
Employees906 Current Ratio3.40 Sales Q/Q-29.60% Oper. Margin-93.90% RSI (14)35.87 Volatility7.47% 8.50%
OptionableYes Debt/Eq0.34 EPS Q/Q-34.40% Profit Margin-94.30% Rel Volume0.89 Prev Close10.31
ShortableYes LT Debt/Eq0.34 EarningsNov 08 AMC Payout- Avg Volume1.56M Price10.15
Recom2.80 SMA20-14.94% SMA50-27.77% SMA200-33.37% Volume1,394,281 Change-1.55%
Jul-17-18Resumed Stifel Buy $72
Jul-16-18Downgrade BofA/Merrill Neutral → Underperform
Nov-10-17Reiterated Stifel Buy $57 → $39
Nov-10-17Reiterated Stifel Buy $39 → $57
Dec-29-16Initiated Northland Capital Outperform $40
May-03-16Initiated JMP Securities Mkt Outperform
Mar-01-16Reiterated Stifel Buy $69 → $57
Mar-01-16Reiterated Mizuho Neutral $28 → $29
Jan-25-16Reiterated Mizuho Neutral $42 → $28
Nov-11-15Upgrade Mizuho Underperform → Neutral $45 → $42
Oct-19-15Reiterated Wunderlich Buy $70 → $50
Oct-14-15Initiated BofA/Merrill Neutral $35
Sep-21-15Initiated Stifel Buy $69
Aug-11-15Downgrade Mizuho Neutral → Underperform $45
Aug-11-15Downgrade JP Morgan Overweight → Neutral
Jul-27-15Reiterated Wunderlich Buy $55 → $70
Jun-09-15Initiated Wunderlich Buy $55
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-03-15Reiterated Mizuho Buy $32 → $50
Jan-23-15Reiterated Mizuho Buy $30 → $32
Nov-09-18 02:08PM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3 Zacks -18.53%
07:00AM  Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and Intrexon ACCESSWIRE
Nov-08-18 11:16PM  Edited Transcript of XON earnings conference call or presentation 8-Nov-18 10:30pm GMT Thomson Reuters StreetEvents
04:10PM  Intrexon Announces Third Quarter 2018 Financial Results PR Newswire
07:56AM  A Preview Of Intrexon's Q3 Earnings Benzinga
Nov-02-18 07:30AM  AquaBounty Technologies, Inc. Results for the quarter and nine months ended September 30, 2018 GlobeNewswire
Nov-01-18 03:37PM  Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp. PR Newswire +9.69%
07:30AM  Intrexon to Announce Third Quarter 2018 Financial Results on November 8th PR Newswire
Oct-29-18 05:14PM  Bragar Eagel & Squire, P.C. is Investigating Intrexon Corporation (XON) on Behalf of Stockholders and Encourages XON Investors to Contact the Firm GlobeNewswire
07:30AM  ActoBio Therapeutics Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes PR Newswire
Oct-25-18 06:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE
10:43AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intrexon Corporation (XON) ACCESSWIRE
Oct-24-18 07:30AM  Intrexon Announces the Formation of Bioinformatics Hub in Munich PR Newswire -15.37%
Oct-23-18 03:05PM  Gaithersburg biotech CEO to step down American City Business Journals
08:40AM  Report: Exploring Fundamental Drivers Behind Q2, Badger Meter, Tiffany, Walgreens Boots Alliance, Intrexon, and Denali Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-18-18 08:43AM  Oxitec to Develop 2nd Friendly Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes PR Newswire
Oct-16-18 05:28PM  AquaBounty receives construction loan to support development efforts at its Rollo Bay property GlobeNewswire +5.06%
04:56PM  INVESTIGATION UPDATE for XON, APOG and ATASY: Levi & Korsinsky, LLP Reminds Investors of Investigations on Behalf of Shareholders GlobeNewswire
Oct-12-18 07:38PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON GlobeNewswire
Oct-09-18 07:00AM  Ziopharm and Precigen Redefine Relationships, Announce New License Agreement GlobeNewswire
Oct-03-18 09:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE
Sep-26-18 07:52PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE
Sep-25-18 03:00PM  Intrexons Latest Pitch: Were a Pot Stock Motley Fool -9.33%
08:45AM  Implied Volatility Surging for Intrexon (XON) Stock Options Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Intrexon and Tilray ACCESSWIRE
07:30AM  Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-24-18 05:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE +31.52%
01:31PM  Merger Mania: Examining the Latest M&A News & Trends | Free Lunch Zacks
11:42AM  Intrexon, Once a Fighter of Zika, Pivots to Join Pot Mania Bloomberg
11:40AM  Why Intrexon Corporation Is Skyrocketing Today Motley Fool
07:30AM  Intrexon Announces Advances in Production of Medical Cannabis PR Newswire
Sep-18-18 08:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE
12:25PM  How to Make a Killing in Gene Therapy Barrons.com
Sep-17-18 10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intrexon Corporation (XON) PR Newswire
Sep-14-18 07:16PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON PR Newswire
01:53PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intrexon Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:14AM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Intrexon Corporation XON Business Wire
Sep-13-18 06:12PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Intrexon Corporation GlobeNewswire
Sep-12-18 07:56AM  Germantown's Intrexon leaving the NYSE for Nasdaq American City Business Journals
06:30AM  Intrexon Announces Transfer of Stock Listing to Nasdaq PR Newswire
Sep-10-18 03:30PM  Black Soldier Fly Larvae Ingredients Receive FDA Recommendation for Poultry Diets PR Newswire
Sep-04-18 09:15AM  CORRECTING and REPLACING -- Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors GlobeNewswire
07:30AM  Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors GlobeNewswire
Aug-27-18 12:05AM  Edited Transcript of XON earnings conference call or presentation 9-Aug-18 9:30pm GMT Thomson Reuters StreetEvents
Aug-14-18 07:35AM  Research Report Identifies Acushnet, Capitol Federal Financial, Laredo Petroleum, Intrexon, Corning, and Idera Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-10-18 12:31PM  Why Intrexon Corporation Stock Is Slipping Today Motley Fool
10:27AM  Intrexon Reports Preliminary Earnings and Revenues for Q2 Zacks
08:00AM  Today's Research Reports on Trending Tickers: Omeros and Intrexon ACCESSWIRE
Aug-09-18 04:57PM  Intrexon Business Update and Conference Call PR Newswire
03:30PM  Intrexon Corporation to Host Earnings Call ACCESSWIRE
Aug-07-18 07:30AM  Ziopharm Oncology Announces Changes to its Board of Directors GlobeNewswire +6.85%
07:00AM  AquaBounty Technologies, Inc. Results for the quarter and six months ended June 30, 2018 GlobeNewswire
Aug-03-18 07:30AM  Intrexon to Present at the Jefferies 2018 Global Industrials Conference PR Newswire
Aug-02-18 07:30AM  Intrexon to Announce Second Quarter and First Half 2018 Financial Results on August 9th PR Newswire
Jul-31-18 05:09PM  What's in Store for Intrexon (XON) This Earnings Season? Zacks
07:45AM  Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8 GlobeNewswire
Jul-26-18 12:05PM  Ziopharm Oncology Board Responds to Recent Stock Price Decline GlobeNewswire
Jul-22-18 07:30PM  The Global Cannabis Market Is Set To Explode Oilprice.com
Jul-11-18 07:20AM  Free Technical Research on Intrexon and Three More Biotech Equities ACCESSWIRE
Jul-10-18 04:00PM  Company Lends Stock to Bank. Bank Shorts Stock to Company's CEO. Any Questions? Bloomberg
11:06AM  Deutsche Bank Brought in Some Help Bloomberg
Jun-29-18 06:00AM  Intrexon Announces Pricing of Offerings of Convertible Senior Notes and Common Stock PR Newswire
Jun-28-18 04:01PM  Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO® GlobeNewswire
Jun-27-18 04:47PM  Intrexon Announces Proposed Offerings of Convertible Senior Notes and Common Stock PR Newswire -6.29%
Jun-20-18 08:00AM  Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Intrexon ACCESSWIRE
Jun-19-18 09:44AM  Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes PR Newswire
09:35AM  Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes PR Newswire
Jun-18-18 06:59PM  Cramer's lightning round: Medical device stocks tend to w... CNBC Videos
06:48PM  Cramer's lightning round: Medical device stocks tend to win big CNBC
07:30AM  Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy GlobeNewswire
Jun-11-18 04:12AM  Intrexon (XON) Down 9.2% Since Earnings Report: Can It Rebound? Zacks
Jun-04-18 07:56AM  Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-31-18 10:26AM  Does Intrexon Corporations (NYSE:XON) Latest Financial Perfomance Look Strong? Simply Wall St.
May-29-18 08:00AM  Isolation and Recombinant Expression of Key Enzyme for Opioid Production PR Newswire
May-24-18 07:00AM  Oxitec Launches Field Trial in Brazil for Next Generation Addition to Friendly Mosquitoes Platform PR Newswire
May-23-18 08:11AM  The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti PR Newswire
May-21-18 08:00AM  Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001 PR Newswire
May-16-18 05:00PM  Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
07:45AM  Recent Analysis Shows H&R Block, Opko Health, Geron, Cardinal Health, Corning, and Intrexon Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
May-14-18 08:00AM  Todays Research Reports on Stocks to Watch: Intrexon and Supernus Pharmaceuticals ACCESSWIRE
08:00AM  Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference PR Newswire
07:10AM  Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE
May-12-18 01:47AM  Edited Transcript of XON earnings conference call or presentation 10-May-18 9:30pm GMT Thomson Reuters StreetEvents
May-11-18 04:00PM  Here's What's Causing Intrexon to Tumble 20% Today Motley Fool -19.64%
09:42AM  Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss Zacks
08:30AM  Today's Research Reports on Trending Tickers: Intrexon Corporation and Synergy Pharmaceuticals ACCESSWIRE
May-10-18 04:05PM  Intrexon Announces First Quarter 2018 Financial Results PR Newswire
04:01PM  Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-08-18 04:45PM  AquaBounty Technologies, Inc. Results for the quarter ended March 31, 2018 GlobeNewswire
May-03-18 08:00AM  Intrexon to Announce First Quarter 2018 Financial Results on May 10th PR Newswire
May-02-18 10:54AM  What's in Store for Intrexon (XON) This Earnings Season? Zacks
07:57AM  Ziopharm Oncology to Announce First Quarter 2018 Financial Results, Host Conference Call May 10 GlobeNewswire
Apr-27-18 11:15AM  AquaBounty Technologies, Inc. Announces FDA Approval of First U.S. Facility for Commercial Production of AquAdvantage Salmon GlobeNewswire
Apr-16-18 07:00AM  Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use PR Newswire
Apr-13-18 11:43AM  Is Intrexon Corporation (NYSE:XON) As Strong As Its Balance Sheet Indicates? Simply Wall St.
Apr-06-18 08:19AM  Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc. Motley Fool
Apr-03-18 08:20AM  Todays Research Reports on Trending Tickers: Intrexon and Portola Pharmaceuticals ACCESSWIRE +7.09%
Apr-02-18 04:11AM  Why Is Intrexon (XON) Up 18.8% Since Its Last Earnings Report? Zacks
Mar-29-18 09:25AM  ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes PR Newswire
Mar-13-18 09:00AM  Newman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XON Business Wire
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LIFFMAN JOEL DSVP, FinanceOct 15Sale14.5979,0001,152,80879,500Oct 17 07:51 PM
Sabzevari HelenPresident, Precigen, Inc.Jul 18Sale14.548,402122,16516,598Jul 19 06:03 PM
KIRK RANDAL JChief Executive OfficerJul 03Buy13.377,479,43199,999,99215,937,319Jul 06 04:46 PM
ALVAREZ CESAR LDirectorFeb 20Option Exercise2.648,90623,512114,849Feb 22 04:51 PM
Frank StevenDirectorFeb 12Option Exercise2.648,90623,512189,093Feb 14 08:06 PM
KIRK RANDAL JChief Executive OfficerJan 19Buy12.501,000,00012,500,0007,782,622Jan 22 09:04 AM
KIRK RANDAL J10% OwnerDec 11Buy0.772,727,2732,100,0005,773,626Dec 13 05:28 PM